BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026)

BridgeBio Pharma has reported Free Cash Flow for 9 years, with the latest figure at -$197.3 million in Q1 2026.

• Quarterly Free Cash Flow rose 0.95% year-over-year to -$197.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$445.1 million (up 10.98% YoY) and the FY2025 annual result came in at -$447.0 million, up 14.2% from the prior year.
• Free Cash Flow declined to -$197.3 million in Q1 2026 per BBIO's latest filing, from -$57.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $75.3 million in Q2 2024 and troughed at -$220.2 million in Q1 2024.
• A 5-year average of -$124.6 million and a median of -$132.0 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 245.17% in 2023, then surged 166.2% in 2024.
• Over 5 years, Free Cash Flow stood at -$98.0 million in 2022, then declined by 27.27% to -$124.7 million in 2023, then slumped by 56.61% to -$195.3 million in 2024, then soared by 70.56% to -$57.5 million in 2025, then slumped by 243.18% to -$197.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$197.3 million, -$57.5 million, and -$109.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.